Feature Article

Clinical Applications of PARP Inhibitors in Breast, Ovarian, and Prostate Cancer: Current Insights and Future Directions

Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)–deficient cancers, especially those with BRCA1/2 mutations. Since […]

Prostate Cancer In Focus

Targeting Human Kallikrein 2 in Prostate Cancer

H&O What is human kallikrein 2 (KLK2), and what makes it a good target in prostate cancer? MS KLK2 is a membrane-associated protease that is involved […]

Advances in Drug Development

The Development of Second-Generation KRAS Inhibitors

H&O How common are KRAS mutations in patients with various types of cancer? EO Approximately 20% to 25% of patients with cancer will have a RAS […]

CRC in Focus

Targeting BRAF V600E Mutations in Metastatic Colorectal Cancer

H&O How common is BRAF V600E–mutated colorectal cancer (CRC)? SK BRAF V600E mutations occur in approximately 5% to 7% of patients with metastatic CRC. That percentage […]

CLL in Focus

Active Treatment in High-Risk, Early-Stage CLL or SLL

H&O How often do patients present with asymptomatic, early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and how many of these patients experience progression […]

Letter From the Editor

Letter From the Editor: Artificial Education

Cancer is a field that requires continuous education. Nearly all the treatments I use today for my patients with prostate, bladder, or kidney cancer did not […]